RUKOBIA, a first-in-class attachment inhibitor, was developed specifically for HIV-1 adults who are heavily treatment-experienced (HTE) and failing therapy.1,2 RUKOBIA is an option for HTE patients with unique risks and challenges.
About HTE patients
Some HTE patients are in critical need of viable ARV options.3
The factors that can limit their ARV options are3:
- Drug resistance
- Safety and tolerability concerns
- Drug interactions
Failing ARV regimens can leave some HTE patients:
Struggling to maintain virologic suppression2
- At increased risk of transmission4
With low CD4+ T-cell counts
- Immunocompromised and increased risk of opportunistic infections4
- At high risk of progression to AIDS and death1,4,5
For additional resources regarding the Story of RUKOBIA
CHECK BACK SOON
- Data on file, ViiV Healthcare.
- Panel on Antiretroviral Guidelines for Adults and Adolescents. Guidelines for the use of antiretroviral agents in adults and adolescents with HIV. Department of Health and Human Services. https://aidsinfo.nih.gov/contentfiles/lvguidelines/adultandadolescentgl.pdf. Updated December 18, 2019. Accessed March 3, 2020.
- Thompson M, Lalezari JP, Kaplan R, et al. Safety and efficacy of the HIV-1 attachment inhibitor prodrug fostemsavir in antiretroviral-experienced subjects: week 48 analysis of AI438011, a Phase IIb, randomized controlled trial. Antivir Ther. 2017;22(3):215-223.
- US Department of Health and Human Services. Guidelines for the prevention and treatment of opportunistic infections in adults and adolescents with HIV: recommendations from the Centers for Disease Control and Prevention, the National Institutes of Health, and the HIV Medicine Association of the Infectious Diseases Society of America. https://aidsinfo.nih.gov/contentfiles/lvguidelines/adult_oi.pdf. Accessed March 3, 2020.
- HIV treatment and care. Centers for Disease Control and Prevention website. https://www.cdc.gov/hiv/clinicians/treatment/treatment-clinicians.html. Accessed March 3, 2020.